Polysubstituted benzimidazoles as antiviral agents
AssigneeThe Regents of the University of Michigan
InventorsLeroy B. Townsend, John C. Drach
Life of this patent
Estimating the term…
Abstract
This invention relates to novel polysubstituted benzimidazoles and compositions and their use in the treatment of viral infections. The polysubstituted benzimidazoles and compositions of the present invention exhibit antiviral properties against viruses of the herpes family, particularly human cytomegalovirus (HCMV) and herpes simplex viruses (HSV).
Claims14
An antiviral compound selected from the group consisting of compounds having the following formula, and pharmaceutically acceptable salts thereof:
- ##STR6## wherein:
- R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is NH.sub.2 and R.sub.6 is 2'-deoxy-.beta.-D-erythropentofuranosyl (denoted compound 113 in the text);
- R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-arabinofuranosyl (denoted compound 134 in the text);
- and
- R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is 5'-O-acetyl-.beta.-D-ribofuranosyl (denoted compound 42a in the text).
An antiviral composition comprising a pharmaceutically acceptable carrier and an compound selected from the group consisting of compounds having the following formula, and pharmaceutically acceptable salts thereof:
- ##STR7## wherein:
- R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is NH.sub.2 and R.sub.6 is 2'-deoxy-.beta.-D-erythropentofuranosyl (denoted compound 113 in the text);
- R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-arabinofuranosyl (denoted compound 134 in the text);
- R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is 5'-O-acetyl-.beta.-D-ribofuranosyl (denoted compound 42a in the text).
A method for treating a herpes viral infection comprising administering to the infected host a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or formulation thereof, selected from the group consisting of compounds having the following formula:
- ##STR8## wherein:
- R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is NH.sub.2 and R.sub.6 is 2'-deoxy-.beta.-D-erythropentofuranosyl (denoted compound 113 in the text);
- R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-arabinofuranosyl (denoted compound 134 in the text);
- R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is 5'-O-acetyl-.beta.-D-ribofuranosyl (denoted compound 42a in the text);
- and
- R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is 2',3',5'-tri-O-acetyl-.beta.-D-ribofuranosyl (denoted compound 42 in the text).
Dependencies are inferred from the claim text.